title: Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide.
abstract: OBJECTIVE
  To assess whether early measures of fasting blood glucose predict later glycaemic response with once-weekly dulaglutide in patients with Type 2 diabetes mellitus.
  
  
  METHODS
  Post hoc analyses were conducted separately for two phase 3 studies (AWARD-5 and AWARD-1) in patients assigned to once-weekly dulaglutide. Week 2 fasting blood glucose was used as a predictor variable, and glycaemic treatment response was defined by HbA1c response based on a composite efficacy endpoint. The association between fasting blood glucose and the glycaemic response was analysed using chi-square tests.
  
  
  RESULTS
  There was a strong association between fasting blood glucose < 7.9 mmol/l at week 2 and achieving the HbA1c composite efficacy endpoint at week 26 (P < 0.01). Higher fasting blood glucose at week 2, however, did not predict absence of glycaemic response and requires further assessment.
  
  
  CONCLUSIONS
  Fasting blood glucose measured at 2 weeks may be an early and useful predictor of glycaemic response to once-weekly dulaglutide treatment.
authors.affiliation: Grunberger Diabetes Institute, Bloomfield Hills, MI, USA.
authors.forename: G
authors.initials: G
authors.lastname: Grunberger
authors.affiliation: Profil Mainz, Mainz, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Forst
authors.affiliation: Lilly USA, LLC., Indianapolis, IN, USA.
authors.forename: L
authors.initials: L
authors.lastname: Fernández Landó
authors.affiliation: Eli Lilly and Company, Neuilly-Sur-Seine, France.
authors.forename: V
authors.initials: V
authors.lastname: Pechtner
authors.affiliation: Eli Lilly and Company, Houten, The Netherlands.
authors.forename: R
authors.initials: R
authors.lastname: Shaginian
authors.affiliation: Eli Lilly and Company, Indianapolis, IN, USA.
authors.forename: N
authors.initials: N
authors.lastname: Jia
authors.affiliation: Oxford Centre for Diabetes, Endocrinology and Metabolism, and NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
authors.forename: S
authors.initials: S
authors.lastname: Gough
mesh_terms: D001786:Blood Glucose / Q000032:analysis* / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis* / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005215:Fasting / Q000097:blood*; D005260:Female; D004763:Glucagon-Like Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007141:Immunoglobulin Fc Fragments / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011237:Predictive Value of Tests; D011379:Prognosis; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins; D004763:Glucagon-Like Peptides; C555680:dulaglutide